Concord Biotech IPO opens. Should you subscribe to the issue?

August 4, 2023

Analysts advised investors to subscribe to Concord Biotech IPO given its complex product portfolio, presence in niche space, strong client relationship and high entry barriers. The company is one of the leading global manufacturers of select fermentation-based APIs (F-APIs) across immunosuppressants and oncology with a market share of over 20% by volume in 2022.

More To Explore

CEAT Q3 Results: Net profit falls 46% to Rs 97 crore on high raw materials cost

CEAT Ltd’s Q3 consolidated net profit fell by 46.48% to Rs 97.03 crore due to high raw material costs. Revenue grew to Rs 3,299.9 crore,

January 15, 2025

Tech View: Nifty’s near-term trend weak; breakout above 23,350 may trigger upside bounce. How to trade on Thursday

The Nifty’s near-term trend remains weak, with the lower tops and bottoms pattern intact. The current pullback aligns with a potential new lower top, pending

January 15, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003